Compare Gilead Sciences, Inc. (GILD) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs JD.Com Inc — how do they compare? Gilead Sciences, Inc. trades at $133.61 (market cap $163.51B), while JD.Com Inc trades at $29.78 (market cap $40.31B). The key difference: Gilead Sciences, Inc. is far larger — about 4.1× JD.Com Inc's market cap, and JD.Com Inc pays the higher dividend (3.42%). Which is the better fit depends on your goals.
| GILD | JD | |
|---|---|---|
Market Cap | $163.51B | $40.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $36.17 |
52-Week Low | $108.22 | $25.19 |
Enterprise Value | $178.05B | $26.46B |
Dividend Yield | 2.49% | 3.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
JD.com (JD) trades at $29.77, up 3.22% today, with strong analyst consensus pointing to a $39.50 price target. The stock shows bullish technical signals and has beaten earnings estimates in recent quarters, though net income margin compressed to 1.05% in 2025. Recent news highlights institutional interest and Zacks Strong Buy rating as of July 14, 2026.
The outlook remains positive given valuation discounts (P/S 0.22) and earnings beats, but risks include ongoing legal investigations and Chinese market volatility. Upside potential is supported by cash flow strength and buyback programs, yet investors should weigh margin pressures against growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
